Principal determinants of the length of remission of psoriasis vulgaris after topical, NB-UVB, and PUVA therapy: A follow-up study

American Journal of Clinical Dermatology

Volumn 14, Issue 1, 2013, Pages 49-53

  Coimbra, Susana ^a,b   Oliveira, Hugo ^c   Belo, Luís ^a,d   Figueiredo, Américo ^c   Rocha Pereira, Petronila ^a,e   Santos Silva, Alice ^a,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b Polytechnic Health Institute of North   (Portugal)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE; C REACTIVE PROTEIN; CALCIPOTRIOL; PSORALEN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; FEMALE; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PUVA; REMISSION; ULTRAVIOLET B RADIATION;

ADMINISTRATION, CUTANEOUS; ADULT; BODY MASS INDEX; C-REACTIVE PROTEIN; DERMATOLOGIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PSORIASIS; PUVA THERAPY; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; ULTRAVIOLET THERAPY;

EID: 84873878136     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-012-0002-8     Document Type: Article

References (15)

1. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol. 1999;41(1):51-9.
2. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. The inflammatory response in mild and in severe psoriasis. Br J Dermatol. 2004;150(5):917-28.
3. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol. 2010;24(7):789-96.
4. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol. 2010;24(12):1386-94.
5. Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol. 2007;157(4):649-55.
6. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, et al. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatol Sci. 2009;55(3):202-4.
7. Friedewald VE Jr, Cather JC, Gordon KB, Kavanaugh A, Ridker PM, Roberts WC. The editor's roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol. 2008;101(8):1119-26.
8. Sakai R, Matsui S, Fukushima M, Yasuda H, Miyauchi H, Miyachi Y. Prognostic factor analysis for plaque psoriasis. Dermatology. 2005;211(2):103-6.
9. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, et al. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study. Am J Clin Dermatol. 2010;11(6):423-32.
10. van de Kerkhof PC. On the limitations of the psoriasis area and severity index (PASI). Br J Dermatol. 1992;126(2):205.
11. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004;51(4):563-9.
12. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64 Suppl 2:ii65-8 (discussion ii9-73).
13. Brazzelli V, Barbagallo T, Prestinari F, Rona C, De Silvestri A, Trevisan V, et al. Non-invasive evaluation of tacalcitol plus puva versus tacalcitol plus UVB-NB in the treatment of psoriasis: "right-left intra-individual pre/post comparison design". Int J Immunopathol Pharmacol. 2005;18(4):755-60.
14. Karrer S, Eholzer C, Ackermann G, Landthaler M, Szeimies RM. Phototherapy of psoriasis: comparative experience of different phototherapeutic approaches. Dermatology. 2001;202(2):108-15.
15. Yones SS, Palmer RA, Garibaldinos TT, Hawk JL. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol. 2006;142(7):836-42.